Business Context and Reporting Period
This Form 8-K Current Report was filed by MEI Pharma, Inc. on April 3, 2017. The filing addresses Item 5.02 regarding the departure of a former officer and the appointment of a new Chief Financial Officer (CFO) and Secretary. The report details the transition of leadership within the company's finance department effective immediately on the filing date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of New CFO: Brian G. Drazba was appointed as Chief Financial Officer and Secretary, effective April 3, 2017.
- Departure of Former CFO: Thomas M. Zech retired as Chief Financial Officer and Secretary concurrently with Mr. Drazba's appointment.
- Consulting Arrangement: Mr. Zech will remain with the company as a consultant until June 30, 2017.
Compensation, Outlook, and Risks
New CFO Compensation (Brian G. Drazba)
- Base Salary: $350,000 annually.
- Bonus: Eligible for a discretionary annual bonus targeted at 40% of base salary, beginning in the fiscal year ending June 30, 2018.
- Equity Grant: Initial stock option grant for 150,000 shares of common stock at the closing price on April 3, 2017.
- Vesting Schedule: One-quarter cliff vests on April 3, 2018; the remainder vests monthly over the subsequent three years (ending April 3, 2021). Options vest immediately upon a change in control.
- Termination Benefits: Eligible for additional compensation upon termination by the company other than for "Cause" or by the officer for "Good Reason."
Former CFO Transition (Thomas M. Zech)
- Consulting Fee: Total cash compensation of $48,000 for the period from April 3, 2017, through June 30, 2017.
- Bonus Eligibility: Remains eligible for a pro-rated fiscal year bonus based on corporate goals.
- Option Extension: The exercise period for outstanding options has been extended to 27 months following retirement, rather than the standard three months post-termination.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason" regarding termination benefits.
- Confirm the closing stock price on April 3, 2017, to determine the exercise price of the 150,000 options granted to Mr. Drazba.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the leadership change.
- Note that the filing does not provide updated financial guidance or operational outlook beyond the personnel announcement.